Regeneron Pharmaceuticals, Inc. (REGN) on Decifer

Why it ranks here

• Sales are growing about 9% a year, faster than 38 in 100 companies we measure.
• It keeps about 28 cents of every sales dollar as cash, safer than 90 in 100 companies we measure.
• It earns about 9% a year on the money put into the business, better than 51 in 100 companies we measure.
• It costs about 20 times its yearly profit; the middle of its industry is 23. Cheaper than 65 in 100 companies we measure, against their own industries.

The current read

The evidence on REGN lines up on the supportive side: a live market force supports this name through its theme connection. The independent signals we track are telling the same story.

Read the full REGN research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.